A5101674987- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Immunodeficiency and Autoimmune Disorders
- Urticaria and Related Conditions
- Aortic aneurysm repair treatments
- Sinusitis and nasal conditions
- Blood disorders and treatments
- IL-33, ST2, and ILC Pathways
- Gastrointestinal disorders and treatments
- Infectious Aortic and Vascular Conditions
- Eosinophilic Esophagitis
- Drug-Induced Adverse Reactions
- IgG4-Related and Inflammatory Diseases
- Food Allergy and Anaphylaxis Research
- Congenital gastrointestinal and neural anomalies
- Ocular Surface and Contact Lens
- Neuroendocrine Tumor Research Advances
- Intestinal Malrotation and Obstruction Disorders
- Immune Cell Function and Interaction
- Mast cells and histamine
- Platelet Disorders and Treatments
- Connective tissue disorders research
- Diverticular Disease and Complications
- Eosinophilic Disorders and Syndromes
Washington University in St. Louis
2000-2024
AllerGen
2020
Cincinnati Children's Hospital Medical Center
2013-2017
St. Michael's Hospital
2011
University of Toronto
2011
University of British Columbia
2006-2008
St. Paul's Hospital
2007
Abdominal aortic aneurysms represent a life-threatening condition characterized by chronic inflammation, destructive remodeling of the extracellular matrix, and increased local expression matrix metalloproteinases (MMPs). Both 92-kD gelatinase (MMP-9) macrophage elastase (MMP-12) have been implicated in this disease, but it is not known if either necessary aneurysmal degeneration. We show here that transient perfusion mouse aorta results delayed aneurysm development temporally associated...
Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function symptom control placebo in adults adolescents with severe, uncontrolled asthma. We assessed efficacy patients severe or without nasal polyps (NPs) 2 years before randomization NAVIGATOR. Methods: Patients...
Severe asthma is complex; comorbidities may influence disease outcomes.
Cytokines, such as interleukins (IL)-4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated patients aged 6-11 years with asthma or without evidence (baseline serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific ≥0.35kU/L).
A 47‐year‐old woman underwent bilateral lung transplantation for nonspecific interstitial pneumonitis and received donor lungs from a 12‐year‐old patient with known peanut allergy. Post‐transplant, the experienced four anaphylaxis‐like reactions. skin prick test to was initially positive; however, it steadily declined over serial assessments reverted negative one year post‐transplant. The subsequently had oral challenge. Transfer of food allergy post‐transplantation is theorized occur via...
Abstract Background Real-world data on transitioning to Immune Globulin Subcutaneous (Human) 20% solution (Ig20Gly) are limited. This study aimed assess infusion parameters and experience of patients with primary (PID) or secondary immunodeficiencies (SID) Ig20Gly in clinical practice Canada. Methods Patients PID SID who received subcutaneous immunoglobulin (SCIG) for ≥ 3 months before were eligible this multicenter (n = 6), phase 4, non-interventional, prospective, single-arm study....
Background: Omalizumab is a treatment option for pediatric and adult patients with moderate to severe allergic asthma poorly controlled standard inhaled therapies. Clinical trials observational studies have demonstrated the efficacy of omalizumab. There limited real-world evidence on characteristics patterns Canadian receiving Objective: We profiled omalizumab users estimate time discontinuation assess changes in concurrent medication usage before, during, after therapy. Methods: This was...
Background Aspirin‐exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis. Although aspirin desensitization (AD) has emerged as an effective therapeutic option, the natural history AERD without AD remains unclear. Methods A retrospective review was conducted patients who underwent endoscopic sinus surgery (ESS) between 2010 and 2019. The primary outcomes were revision rate time to surgery. Secondary included changes in 22‐item...
Endoscopic mucosal resection (EMR) is a technique that was originally developed in 1978 for early gastric cancer (1). Given the relative simplicity, safety and effectiveness of technique, it has become an endoscopic alternative to surgery resecting flat polypoid neoplasms mucosa by longitudinal section through submucosa curative intent. Moreover, EMR increasingly being used submucosal neoplastic lesions intramucosal cancers. Still considered novel procedure endoscopists outside Japan,...
Schnitzler syndrome encompasses monoclonal gammopathy, urticaria, inflammation, recurrent fever, bone pain and arthralgia, with occasional lymphadenopathy and/or hepatosplenomegaly. It is a rare condition approximately 100 cases reported in the literature. To our knowledge, this first case of cold-induced physical urticaria syndrome.A 43-year-old woman presented to an allergy immunology clinic 7 year history chronic angioedema anaphylaxis, gammopathy pain. Her was triggered by cooler...
Patients with severe allergic asthma (SAA) are at risk of exacerbations. Omalizumab is recommended as an add-on treatment for patients uncontrolled SAA, despite high-dose inhaled corticosteroids and long acting β2-agonist combination therapy (standard therapy).RELIEF was a prospective, open label, multicenter study conducted to assess the real-life effectiveness omalizumab co-administered standard in SAA 24 months.A total 347 aged ≥ 6 years were enrolled, 285 whom (8 pediatrics 277...
<b>About half of the patients who initiate therapy with mepolizumab discontinue treatment within first or second year. Concomitant use short-acting β<sub>2</sub>-agonists and oral corticosteroids drops during use.</b>https://bit.ly/3aRISqS